Department of Neonatology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Department of Neonatology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
BMJ Open Qual. 2024 May 29;13(Suppl 1):e002697. doi: 10.1136/bmjoq-2023-002697.
Sick preterm neonates are most vulnerable to developing skin injuries. Despite sound knowledge and application of evidence-based practices for preventing medical adhesive-related skin injury (MARSI), the incidence of MARSI was 30 events per 1000 adhesive application days in our unit.
We aimed to reduce the median MARSI rate from the existing 30 per 1000 MARSI days to <5 per 1000 MARSI over 5 months from June 2023 to October 2023.
MATERIAL & METHODS: With the point-of-care quality improvement (QI) approach, a prospective study was planned to reduce the incidence of MARSI among sick very preterm newborns (<32 weeks gestational age) and eventually improve overall skin condition during hospital stay. Sequential Plan-Do-Study-Act cycles were implemented based on the identified risk factors recognised during recurring team discussions.
We demonstrated a reduction in the MARSI rate from 30 events per 1000 adhesive applications (during baseline assessment) to zero events per 1000 adhesive applications at the end of the study period. It was temporally related to the assessment of skin risk stratification at admission using a validated tool, regular assessment of neonatal skin condition score based on the skin risk stratification, and reinforcement of MARSI prevention bundle by application of barrier spray. Awareness regarding 'skin injury prevention' bundles was continually generated among healthcare professionals. The MARSI rate remained <5 events per adhesive application in the sustenance phase over 6 months.
Implementing evidence-based skin care practices resulted in a significant reduction in iatrogenic cutaneous injury events in very preterm neonates.
患有疾病的早产儿最容易发生皮肤损伤。尽管我们对预防与医用黏胶相关的皮肤损伤(MARSI)的循证实践有很好的了解和应用,但在我们的单位,MARSI 的发生率为每 1000 个黏胶应用日发生 30 例。
我们的目标是将现有的每 1000 个 MARSI 天 30 例的 MARSI 中位数率降低到 2023 年 6 月至 2023 年 10 月的 5 个月内<5 例/每 1000 例 MARSI。
采用即时质量改进(QI)方法,计划进行一项前瞻性研究,以降低患有疾病的极早产儿(<32 周胎龄)的 MARSI 发生率,并最终改善住院期间的整体皮肤状况。基于反复团队讨论中确定的风险因素,实施了连续的计划-执行-研究-行动循环。
我们证明了 MARSI 发生率从每 1000 个黏胶应用 30 例(基线评估期间)降低到研究期末的每 1000 个黏胶应用零例。这与在入院时使用经过验证的工具评估皮肤风险分层、根据皮肤风险分层定期评估新生儿皮肤状况评分以及通过应用屏障喷雾加强 MARSI 预防包有关。医护人员对“皮肤损伤预防”包的意识不断增强。在维持阶段的 6 个月内,MARSI 率仍保持在每 1000 个黏胶应用<5 例。
实施基于证据的皮肤护理实践显著降低了极早产儿的医源性皮肤损伤事件发生率。